The rapid emergence of Salmonella Typhi with decreased ciprofloxacin susceptibility following an increase in ciprofloxacin prescriptions in Blantyre, Malawi

Ciprofloxacin is the first-line drug for treating typhoid fever in many high burden countries in Africa, but the emergence of non-susceptibility poses a grave challenge to public health programmes. Through enhanced surveillance as part of vaccine evaluation, we set out to investigate the occurrence and determinants of ciprofloxacin non-susceptibility in Blantyre, Malawi. We performed systematic typhoid fever and antibiotic prescription surveillance in two health centres in Blantyre, Malawi between 01/10/2016 and 31/10/2019, as part of the STRATAA and TyVAC studies. Blood culture isolates from study participants underwent i) pefloxacin screening and ciprofloxacin E-tests to identify ciprofloxcain non-susceptibility and ii) whole genome sequencing (WGS) to identify drug resistance mutations and phylogenetic relationships between non-susceptible and sensitive isolates. We constructed generalised linear regression models to investigate associations between ciprofloxacin prescription rates and S. Typhi isolates with Quinolone Resistance Determining Region (QRDR) mutations. We carried out 11295 blood cultures and microbiologically confirmed 239 cases of typhoid fever, with isolates from 193 participants sequenced (mean age of participants with sequenced genomes 12.8 years, 47% male). Between October 2016 and August 2019 2% (n=4/175) of WGS-confirmed typhoid fever cases were caused by S. Typhi with QRDR mutations, compared with 33% (n=6/18) in September and October 2019. Nine of the ten S. Typhi with QRDR mutations had a decreased ciprofloxacin susceptibility phenotype. Every additional prescription of ciprofloxacin given to study participants in the preceding month was associated with a 4.2% increase in the relative risk of isolating S. Typhi with a QRDR mutation (95% CI, 1.8-7.0%, p=0.0008). Phylogenetic analysis showed that S. Typhi isolates with QRDR mutations in September/October 2019 belonged to two distinct sub-clades encoding two different QRDR mutations, and were closely related (0-6 SNPs) to susceptible S. Typhi endemic to Blantyre. We have shown a close temporal association between empiric antimicrobial usage with an increase of fluoroquinolone non-susceptibility in S. Typhi, with two sub-clades responsible for the increase. Decreasing ciprofloxacin usage by improving typhoid diagnostics could help to limit the emergence of resistance.

[1]  P. Ashton,et al.  Genomic epidemiology and antimicrobial resistance transmission of Salmonella Typhi and Paratyphi A at three urban sites in Africa and Asia , 2023, medRxiv.

[2]  R. Kingsley,et al.  Population structure and evolution of Salmonella enterica serotype Typhi in Zimbabwe before a typhoid conjugate vaccine immunization campaign , 2022, bioRxiv.

[3]  Jessica C. Chen,et al.  Molecular characterization of circulating Salmonella Typhi strains in an urban informal settlement in Kenya , 2022, PLoS neglected tropical diseases.

[4]  M. Lipsitch,et al.  Analysis of multiple bacterial species and antibiotic classes reveals large variation in the association between seasonal antibiotic use and resistance , 2022, PLoS biology.

[5]  J. Reynolds,et al.  Understanding antimicrobial use in subsistence farmers in Chikwawa District Malawi, implications for public awareness campaigns , 2021, PLOS global public health.

[6]  G. Dougan,et al.  Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. , 2021, The Lancet. Global health.

[7]  R. Ferrand,et al.  Antibiotic stories: a mixed-methods, multi-country analysis of household antibiotic use in Malawi, Uganda and Zimbabwe , 2021, BMJ Global Health.

[8]  K. Neuzil,et al.  Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial , 2021, The Lancet. Global health.

[9]  R. Heyderman,et al.  Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children , 2021, The New England journal of medicine.

[10]  G. Kang,et al.  Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol. , 2021, Wellcome open research.

[11]  K. Neuzil,et al.  Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial , 2021, The Lancet.

[12]  K. Holt,et al.  Five Years of GenoTyphi: Updates to the Global Salmonella Typhi Genotyping Framework , 2021, bioRxiv.

[13]  G. Dougan,et al.  Multiple introductions of multidrug-resistant typhoid associated with acute infection and asymptomatic carriage, Kenya , 2021, bioRxiv.

[14]  F. Aarestrup,et al.  Salmonella enterica serovar Typhi H58 clone has been endemic in Zimbabwe from 2012 to 2019. , 2020, The Journal of antimicrobial chemotherapy.

[15]  G. Kang,et al.  Phylogenetic Analysis Indicates a Longer Term Presence of the Globally Distributed H58 Haplotype of Salmonella Typhi in Southern India , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Olga Chernomor,et al.  IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.

[17]  E. Owusu-Dabo,et al.  Chromosomal and plasmid-mediated fluoroquinolone resistance in human Salmonella enterica infection in Ghana , 2019, BMC Infectious Diseases.

[18]  Shaohua Zhao,et al.  Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates , 2019, Antimicrobial Agents and Chemotherapy.

[19]  R. Woods,et al.  Bystander Selection for Antimicrobial Resistance: Implications for Patient Health , 2019, Trends in microbiology.

[20]  B. Stray-Pedersen,et al.  Laboratory characterisation of Salmonella enterica serotype Typhi isolates from Zimbabwe, 2009–2017 , 2019, BMC Infectious Diseases.

[21]  David L. Smith,et al.  The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The Lancet. Infectious diseases.

[22]  P. Bork,et al.  Interactive Tree Of Life (iTOL) v4: recent updates and new developments , 2019, Nucleic Acids Res..

[23]  R. Heyderman,et al.  Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Jonathan P Strysko,et al.  Notes from the Field: Typhoid Fever Outbreak - Harare, Zimbabwe, October 2017-February 2018. , 2019, MMWR. Morbidity and mortality weekly report.

[25]  D. Morgan,et al.  Global access to antibiotics without prescription in community pharmacies: A systematic review and meta-analysis. , 2019, The Journal of infection.

[26]  S. Kariuki,et al.  Multi-drug resistant Salmonella enterica serovar Typhi isolates with reduced susceptibility to ciprofloxacin in Kenya , 2018, BMC Microbiology.

[27]  Andrew J. Page,et al.  The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa , 2018, Nature Communications.

[28]  A. Pollard,et al.  A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid , 2018, PLoS neglected tropical diseases.

[29]  Michael Lawrence Barnett,et al.  The distribution of antibiotic use and its association with antibiotic resistance , 2018, bioRxiv.

[30]  J. Marschall,et al.  Intra-hospital differences in antibiotic use correlate with antimicrobial resistance rate in Escherichia coli and Klebsiella pneumoniae: a retrospective observational study , 2018, Antimicrobial Resistance & Infection Control.

[31]  J. Jacobs,et al.  Fluoroquinolone resistance in Salmonella: insights by whole-genome sequencing , 2018, Microbial genomics.

[32]  N. Zmora,et al.  Open label comparative trial of mono versus dual antibiotic therapy for Typhoid Fever in adults , 2018, PLoS neglected tropical diseases.

[33]  L. Kaljee,et al.  Social and Economic Burden Associated With Typhoid Fever in Kathmandu and Surrounding Areas: A Qualitative Study , 2017, The Journal of infectious diseases.

[34]  G. Dougan,et al.  The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys , 2017, BMJ Open.

[35]  Thomas K. F. Wong,et al.  ModelFinder: Fast Model Selection for Accurate Phylogenetic Estimates , 2017, Nature Methods.

[36]  M. Wootton,et al.  Faecal carriage of antibiotic resistant Escherichia coli in asymptomatic children and associations with primary care antibiotic prescribing: a systematic review and meta-analysis , 2016, BMC Infectious Diseases.

[37]  J. Crump,et al.  A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  M. Wootton,et al.  Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis , 2016, British Medical Journal.

[39]  N. Ferguson,et al.  The Ecological Dynamics of Fecal Contamination and Salmonella Typhi and Salmonella Paratyphi A in Municipal Kathmandu Drinking Water , 2016, PLoS neglected tropical diseases.

[40]  Phelim Bradley,et al.  Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis , 2015, Nature Communications.

[41]  Paul Turner,et al.  Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events , 2015, Nature Genetics.

[42]  G. Dougan,et al.  Rapid Emergence of Multidrug Resistant, H58-Lineage Salmonella Typhi in Blantyre, Malawi , 2015, PLoS neglected tropical diseases.

[43]  S. Baker,et al.  Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence. , 2014, Trends in microbiology.

[44]  W. Goessens,et al.  Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[45]  E. Batard,et al.  Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[46]  Heng Li Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[47]  Anthony M. Smith,et al.  Salmonella Typhi in the Democratic Republic of the Congo: Fluoroquinolone Decreased Susceptibility on the Rise , 2012, PLoS neglected tropical diseases.

[48]  I. Fetzer,et al.  Biodegradation of ciprofloxacin in water and soil and its effects on the microbial communities. , 2011, Journal of hazardous materials.

[49]  I. Okeke,et al.  Non-prescription antimicrobial use worldwide: a systematic review. , 2011, The Lancet. Infectious diseases.

[50]  J. Schrenzel,et al.  Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. , 2011, The Journal of antimicrobial chemotherapy.

[51]  S. Karande,et al.  Multidrug-resistant typhoid fever: a review. , 2011, Journal of infection in developing countries.

[52]  B. Cooper,et al.  Improving Quinolone Use in Hospitals by Using a Bundle of Interventions in an Interrupted Time Series Analysis , 2010, Antimicrobial Agents and Chemotherapy.

[53]  Y. Teo,et al.  Typhoid in Kenya Is Associated with a Dominant Multidrug-Resistant Salmonellaenterica Serovar Typhi Haplotype That Is Also Widespread in Southeast Asia , 2010, Journal of Clinical Microbiology.

[54]  Y. Carmeli,et al.  Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  B. Fantin,et al.  Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. , 2009, The Journal of infectious diseases.

[56]  K. Keddy,et al.  Quinolone-resistant Salmonella Typhi in South Africa, 2003–2007 , 2009, Epidemiology and Infection.

[57]  J. Kluytmans,et al.  Correlation between antibiotic use and resistance in a hospital: Temporary and ward-specific observations , 2009, Infection.

[58]  H. Goossens,et al.  Antimicrobial Drug Use and Resistance in Europe , 2008, Emerging infectious diseases.

[59]  M. Edmond,et al.  Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  P. Nabeth,et al.  Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal. , 2005, The Journal of antimicrobial chemotherapy.

[61]  K. Hopkins,et al.  Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. , 2005, International journal of antimicrobial agents.

[62]  J. Wain,et al.  Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.